CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital

Status Completed

Clinical Trial Summary

This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind trial with open-label follow-up designed to assess the efficacy of Xeris Glucagon delivered as a continuous subcutaneous infusion to prevent hypoglycemia with lower intravenous glucose infusion rates in children < 1 year of age with congenital hyperinsulinism.

Clinical Trial Description

This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind (DB) parallel group study with open-label follow-up designed to evaluate the efficacy of CSI-Glucagon™ for the prevention of hypoglycemia with lower IV glucose infusion rates when delivered subcutaneously to patients up to 1 year of age with congenital hyperinsulinism. CSI-Glucagon™ is expected to provide a better inpatient treatment option compared to the current standard of care.

The study will consist of three phases:

1. Baseline Phase: First is a baseline stabilization phase during which concomitant therapy with octreotide and diazoxide will be safely weaned and continuous enteric feed will be held constant to the degree possible, with the only factors varying being meal size and IV glucose infusion rate (GIR) adjusted by a set plasma glucose measurement driven algorithm.

2. Blinded, Randomized Treatment Phase: Following the stabilization phase, subjects will be randomly assigned to blinded treatment with either glucagon or placebo, which will be delivered for up to 48 hours with an OmniPod® infusion pump with the controller set to a starting basal rate for glucagon of 5 μg/kg/hr and GIR adjustments used to maintain euglycemia. After 48 hours of blinded treatment, all subjects will transition to open-label active treatment. However, if GIR reduction from baseline is < 20% at 24 hours, subjects will be transitioned early to the open-label phase.

3. Open-label Treatment Phase: The third study period will involve use of CSI-Glucagon™ to manage blood glucose with minimal GIR for up to 28 days of cumulative exposure. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02937558
Study type	Interventional
Source	Xeris Pharmaceuticals
Contact
Status	Completed
Phase	Phase 2
Start date	October 2016
Completion date	October 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02021604` - Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma	Phase 1
Recruiting	`NCT04732416` - HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)	Phase 2
Completed	`NCT02604485` - A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism	Phase 2
Recruiting	`NCT04205604` - 18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism	Phase 2
Completed	`NCT00897676` - Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity	Phase 1/Phase 2
Completed	`NCT00987168` - Sandostatine® LP and Hyperinsulinism	Phase 2
Active, not recruiting	`NCT03941236` - Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism	Phase 3
Completed	`NCT03042416` - 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety	Phase 3
Completed	`NCT04172441` - Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism	Phase 2/Phase 3
Recruiting	`NCT04706910` - 18F-DOPA II - PET Imaging Optimization	Phase 3
Recruiting	`NCT06208215` - RZ358 Treatment for Congenital Hyperinsulinism	Phase 3
Completed	`NCT03777176` - A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism	Phase 3
Recruiting	`NCT03768518` - GLP-1 Receptor Expression in CHI
Completed	`NCT04538989` - An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism	Phase 2
Completed	`NCT01070758` - Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy	Phase 4
Completed	`NCT00674440` - Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism	Phase 2
Terminated	`NCT00835328` - Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia	Phase 1/Phase 2
Completed	`NCT00571324` - Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism	Phase 1/Phase 2
Withdrawn	`NCT03053284` - Pasireotide in Hyperinsulinemic Hypoglycemia	Phase 2
No longer available	`NCT02835131` - Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms